Grivas P, Loriot Y, Morales-Barrera R, et al. - Among patients with previously treated locally advanced/unresectable or metastatic urothelial carcinoma (UC), this investigation (ATLAS) was carried out to determine whether rucaparib (poly(ADP-ribose) polymerase inhibitor) has efficacy and safety in this patient population. Enrollment of patients with UC was performed independent of tumor homologous recombination deficiency (HRD) status, and these patients were administered rucaparib 600 mg BID. There were 95 evaluable patients, in whom no confirmed responses were obtained. However, decreases in the sum of target lesions were noted, including 6 (6.3%) cases with unconfirmed partial response. Disease control rate and median progression-free survival were identified to be 11.6% and 1.8 months, respectively. In this study, no significant activity of rucaparib was evident in unselected patients with advanced UC irrespective of HRD status. The observed safety profile was consistent with that noted in cases with ovarian or prostate cancer.